WO1991016449A1 - Compositions saccharides et procedes et appareil servant a les synthetiser - Google Patents

Compositions saccharides et procedes et appareil servant a les synthetiser Download PDF

Info

Publication number
WO1991016449A1
WO1991016449A1 PCT/US1991/002430 US9102430W WO9116449A1 WO 1991016449 A1 WO1991016449 A1 WO 1991016449A1 US 9102430 W US9102430 W US 9102430W WO 9116449 A1 WO9116449 A1 WO 9116449A1
Authority
WO
WIPO (PCT)
Prior art keywords
acceptor moiety
glycosyltransferase
saccharide
iteration
pharmaceutical composition
Prior art date
Application number
PCT/US1991/002430
Other languages
English (en)
Inventor
Steve Roth
Original Assignee
The Trustees Of The University Of Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Trustees Of The University Of Pennsylvania filed Critical The Trustees Of The University Of Pennsylvania
Priority to AT91907908T priority Critical patent/ATE225402T1/de
Priority to EP91907908A priority patent/EP0481038B1/fr
Priority to DE69133122T priority patent/DE69133122D1/de
Priority to BR919106345A priority patent/BR9106345A/pt
Priority to KR1019910701867A priority patent/KR920702721A/ko
Publication of WO1991016449A1 publication Critical patent/WO1991016449A1/fr
Priority to NO91914766A priority patent/NO914766L/no
Priority to FI915890A priority patent/FI915890A0/fi
Priority to BG96982A priority patent/BG61170B1/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/18—Preparation of compounds containing saccharide radicals produced by the action of a glycosyl transferase, e.g. alpha-, beta- or gamma-cyclodextrins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/814—Enzyme separation or purification
    • Y10S435/815—Enzyme separation or purification by sorption
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/819—Fermentation vessels in series

Definitions

  • This invention relates to saccharide compositions such as, for example, oligo ⁇ accharides, polysaccharides, glycolipids, and glycoproteins. More specifically, this invention relates to processes for preparing these and other saccharide compositions by enzymatic techniques.
  • carbohydrate embraces a wide variety of chemical compounds having the general formula (CH 2 O) n , such as monosaccharides, disaccharides, oligosaccharides and polysaccharides. Oligosaccharides are chains
  • saccharide units which are alternatively known as sugars. These saccharide units can be arranged in any order and the linkage between two saccharide units can occur in any of approximately ten different ways. As a result, the number of different possible stereoisomeric oligosaccharide chains is enormous.
  • oligosaccharides and polysaccharides have been the least well studied, due in considerable part to the difficulty of sequencing and synthesizing their often complex sugar chains. Although the syntheses of oligonucleotides and polypeptides are well developed, there is currently no generally applicable synthetic technique for synthesizing oligosaccharides.
  • carbohydrates and molecules comprising carbohydrate fragments such as glycolipids and glycoproteins.
  • glycoproteins and glycolipids mediate recognition between cells and cells, between cells and ligands, between cells and the extracellular matrix, and between cells and pathogens.
  • glycoprotein or glycolipid involved in cell recognition The oligosaccharides are believed to compete with the glycoproteins and glycolipids for binding sites on receptor proteins.
  • the disaccharide is believed to compete with the glycoproteins and glycolipids for binding sites on receptor proteins.
  • the disaccharide is believed to compete with the glycoproteins and glycolipids for binding sites on receptor proteins.
  • galactosyl ß 1-4 N-acetylglucosamine is believed to be one component of the glycoproteins which interact with receptors in the plasma membrane of liver cell.
  • oligosaccharides and other sacchariue composii-icns have uie potential to open new horizons in pharmacology, diagnosis, and
  • oligosaccharides stereospecifically and the addition of some sugars, such as sialic acid and fucose, has not been effectively accomplished because of the extreme lability of their bonds. Improved, generally applicable methods for oligosaccharide synthesis are desired for the
  • enzymes have been targeted for use in organic synthesis as one alternative to more traditional techniques.
  • enzymes have been used as catalysts in organic synthesis; the value of synthetic enzymatic reactions in such areas as rate acceleration and stereoselectivity has been demonstrated.
  • techniques are now available for low cost production of some enzymes and for alteration of their properties.
  • nucleoside mono- and diphosphate sugars provide the building blocks for most
  • oligosaccharides UDP-Glc, UDP-GlcUA, UDP-GlcNAc, UDP- Gal, UDP-GalNAc, GGP-Man, GDP-Fuc and CMP-NeuAc. These are the intermediates of the Leloir pathway. A much larger number of sugars (e.g., xylose, arabinose) and oligosaccharides are present in microorganisms and plants.
  • the enzymes of the Leloir pathway is the largest group. These enzymes transfer sugars activated as sugar nucleoside phosphates to a growing oligosaccharide chain. Non-Leloir pathway enzymes transfer carbohydrate units activated as sugar phosphates, but not as sugar nucleoside phosphates.
  • glycosyltransferases The second uses glycosidases or glycosyl hydrolases.
  • Glycosyltransferases catalyze the addition of activated sugars, in a stepwise fashion, to a protein or lipid or to the non-reducing end of a growing
  • glycosyltransferases each of the more than one hundred glycosyltransferases identified to date appears to catalyze the formation of a unique glycidic linkage. To date, the exact details of the specificity of the glycosyltransferases are not known. It is not clear, for example, what sequence of
  • glycosyltransferase must be available at practical cost and the glycosyltransferase must be available.
  • the first issue is resolved for most common NDP-sugars, including those important in mammalian biosynthesis.
  • the problem in this technology however resides with the second issue. To date, only a very small number of glycosyltransferases are available.
  • glycosyltransferases are difficult to isolate, particularly from mammalian source. This is because these proteins are present in low concentrations and are membrane-bound. Further, although a few glycosyltransferases have been
  • glycosyltransferases are available from commercial sources, and these materials are expensive.
  • oligosaccharides oligosaccharides, polysaccharides, glycoproteins, glycolipids, and similar species in an efficient, cost effective, stereospecific, and generally applicable manner.
  • Saccharide compositions having a
  • plurality of saccharide units are preferably prepared by appending the saccharide units in stepwise fashion to acceptor moieties which are themselves saccharide
  • compositions prepared in accordance with this invention comprising the steps of
  • glycosyltransferase is prepared so as to be specific for the acceptor moiety and capable of transferring a
  • composition is intended to include any chemical moiety having a saccharide unit within its structure.
  • oligosaccharides, polysaccharides, glycoproteins, and glycolipids provide examples of saccharide compositions. Mixtures and solutions comprising such moieties are also saccharide compositions.
  • Saccharide compositions are prepared according to this invention by the enzyme facilitated transfer of saccharide units from donor moieties to acceptor
  • saccharide unit stereoselectively, that is, in but one stereoisomeric form.
  • saccharide compositions prepared in accordance with this invention are believed to find wide utility in diagnostics, therapeutics, and pharmacological
  • a retrosynthetic analysis is generally performed to determine an appropriate synthetic scheme for the saccharide composition.
  • Such a synthetic scheme preferably identifies the particular donor
  • a preselected saccharide unit is first enzymatically attached to an initial acceptor moiety, i.e., a protein, a glycoprotein, a lipid, a glycolipid, or a carbohydrate starting material. This is followed by enzymatically attaching preselected saccharide units to the product obtained in a stepwise fashion thereby forming the saccharide composition.
  • an initial acceptor moiety i.e., a protein, a glycoprotein, a lipid, a glycolipid, or a carbohydrate starting material.
  • the present invention is based on the inventor's discovery that the starting material of the synthesis (i.e., the protein, glycoprotein, lipid, glycolipid or carbohydrate) and each intermediate product formed in the synthesis can be advantageously used to obtain, for each corresponding step of the synthesis, a
  • glycosyltransferase specific to catalyze the attachment of the next intermediate product in the synthesis of the target saccharide composition.
  • glycosyltransferase needed for any given step is isolated with the intermediate product (the acceptor moiety) and used to attach to the acceptor moiety the next saccharide unit necessary for construction of the target
  • this process is repeated, with each iteration (time) yielding the particular glycosyltransferase required to attach the next saccharide unit onto the growing molocule being isolated, until the target carbohydrate molecule is obtained.
  • acceptor moiety may be a protein, glycoprotein, lipid, glycolipid, or carbohydrate, such as a monosaccharide, disaccharide, oligosaccharide, or polysaccharide.
  • the acceptor moiety may be a protein, glycoprotein, lipid, glycolipid, or carbohydrate, such as a monosaccharide, disaccharide, oligosaccharide, or polysaccharide.
  • glycosyltransferase is attached to a solid support.
  • the present methods are capable of stereospecific attachment of the saccharide unit to the acceptor moiety.
  • nucleotides as donor moieties, ⁇ ridine, guanosine, and cytidine phosphate materials terminated by the saccharide units to be donated preferably comprise the donor moieties.
  • the present invention thus also provides means for preparing a glycosyltransferase specific for a particular acceptor moiety and capable of transferring a preselected saccharide unit to the acceptor moiety.
  • Such methods comprise contacting the acceptor moiety with a mixture suspected to contain a plurality of glycosyltransferases under conditions effective to bind the acceptor moiety and the glycosyltransferase specific for the acceptor moiety.
  • the resulting, bound glycosyltransferase is
  • glycosyltransferase be sequenced and that the
  • glycosyltransferase be produced in enhanced quantities by genetic engineering techniques.
  • glycosyltransferase of interest may be identified as follows. For the most common glycosidic linkages, the glycosyltransferase activities have been described in publications. This is largely true for compounds like milk oligosaccharides, or the carbohydrate moieties of typical (i.e., prevalent) glycoproteins and glycolipids. For less well described linkages, one may first look to the tissue, organ, foodstuff organism, in which the linkage is found. Generally, if the linkage is found in a particular source, the enzyme that made the linkage is also present in the .source.
  • the source is homogenized.
  • the enzyme is purified from homogenate by affinity
  • the homogenate is passed over a solid matrix having immobilized thereon the acceptor moiety under conditions which cause the glycosyltransferase to bind to the acceptor moiety.
  • the solid support matrix having the glycosyltransferase bound thereto is then washed. This is followed by an elution step in which the glycosyltransferase is desorbed from the solid support matrix and collected.
  • glycosyltransferase may be eluted, for example, by passing an aqueous salt (e.g. NaCl) solution over the solid support matrix.
  • aqueous salt e.g. NaCl
  • the "enzyme" purified from the homogenate by affinity chromatography and which is used to attack a preselected saccharide unit onto the acceptor moiety comprises a mixture of various glycosyltransferases which have been purified from other extraneous biological material present in the homogenate which includes enzymes which can interfere with the desired activity of the purified glycosyltransferases.
  • the glycosyltransferases used in accordance with the present invention is frequently a mixture of various "glycosyltransferase". If desired, this material may be further purified with a single purified
  • glycosyltransferase being isolated and used in the process of the present invention, but such further purification is generally not necessary.
  • acceptor moiety is provided which is capable of being covalently bound to a preselected saccharide unit.
  • acceptor moieties include proteins, glycoproteins, lipids, glycolipids and carbohydrates. It will be appreciated that acceptor moieties are preferred to the extent that they are present as a structural component of a saccharide composition of interest. For example, in preparing a saccharide composition such as N-acetylneuraminyl ⁇ 2-3 galactosyl ⁇ 1-4
  • N-acetylglucosamine preferred acceptor moieties would be N-acetylglucosamine and galactosyl ⁇ 1-4
  • N-acetylglucosamine N-acetylglucosamine. It will likewise be appreciated that where an acceptor moiety is terminated by a saccharide unit, subsequent saccharide units will typically be covalently bound to the nonreducing terminus of the terminal saccharide.
  • the saccharide unit to be transferred to an acceptor moiety is provided by a donor moiety for the saccharide unit.
  • a donor moiety according to this invention includes the saccharide unit to be transferred and is capable of providing that saccharide unit to the acceptor moiety when contacted by the acceptor moiety and the appropriate glycosyltransferase.
  • Preferred donor moieties are
  • saccharide nucleotides such as saccharide-terminated uridine phosphates, saccharide-terminated guanosine phosphates, and saccharide-terminated cytidine
  • donor moieties are preferred to be capable of readily providing their component saccharide unit to an acceptor moiety when placed in contact therewith and with a
  • glycosyltransferase For example, uridine diphosphate galaotose is preferred for transferring galactose to N-acetylglucosamine, while cytidine monophosphate N- acetylneuraminic acid is preferred for transferring N- acetylneuraminic acid, a sialic acid, to galactosyl ⁇ 1-4 N-acetylglucosamine.
  • a glycosyltransferase for each
  • glycosyltransferase may be broadly defined as an enzyme which facilitates the transfer of a saccharide unit from one chemical moiety (here defined as a donor) to another (here defined as an acceptor) and which is named phenomenologically according to the saccharide unit it transfers.
  • fucosyltransferase transfers fucose.
  • Glycosyltransferases according to this invention are those able to effect the transfer of a predetermined saccharide unit to an acceptor moiety.
  • Glycosyltransferases are preferably specific for an acceptor moiety or at least some significant, active, or exposed portion thereof. Specificity is manifested for a glycosyltransferase by its tendency to bind with a particularly sequenced portion of an acceptor moiety when placed in contact or close proximity therewith and to effect the transfer of a particular saccharide unit to that acceptor moiety.
  • glycosyltransferases are available only from natural sources and, as a result, are somewhat limited in number. It will be appreciated that known glycosyltransferases are only capable of effecting saccharide unit transfers which are highly specific, both in terms of the chemical identity of the saccharide unit transferred and the stereochemistry of its subsequent attachment to the acceptor moiety. For example, it is known that one N-acetylneuraminyltransferase can effect the transfer of N-acetylneuraminic acid to an acceptor moiety bearing only a galactose unit to produce a saccharide composition having an a 2-3 linkage between the N-acetylneuraminic acid unit and the galactose unit.
  • the invention permits construction of sugar linkages found in nature.
  • the linkage of galactose ⁇ 1-2 to N-acetylneuraminic acid which has not been found in nature, cannot presently be effected.
  • the methods disclosed herein are, however, applicable to any type of glycosyltransferase which may become available. While the behavior of a number of
  • glycosyltransferases is known, most glycosyltransferases are currently not fully characterized.
  • the present invention provides methods by which all
  • glycosyltransferases amenable to its practice may be identified and prepared. It has now been found that an acceptor moiety can be used as an affinity
  • an acceptor moiety is immobilized as, for example, on a solid support.
  • solid support includes semi-solid supports as well.
  • immobilized acceptor moiety will bind an enzyme specific for it, this system is then monitored for acceptor-bound enzyme.
  • Monitoring for acceptor-bound enzyme may be carried out as follows.
  • the cell homogenate is passed over the immobilized acceptor moiety. This may be achieved, for example, by passing the cell homogenate over a column charged with immobilized acceptor moiety. The column is then washed and the amount of protein which passes
  • the acceptor and the candidate enzyme are again contacted, this time in the presence of a donor moiety which comprises the saccharide unit desired to be transferred to the exceptor moiety. If such contacting results in the transfer of the saccharide unit to the acceptor, the enzyme is a glycosyltransferase useful in the practice of this invention.
  • glycosyltransferase is identified, it can be sequenced and/or replicated by techniques well-known to those skilled in the art. For example, replication might be accomplished by recombinant techniques involving the isolation of genetic material coding for the
  • glycosyltransferase and the preparation of an immortal cell line capable of producing the glycosyltransferase. Replication will likely prove desirable for commercial scale production of saccharide compositions in accordance with this invention.
  • the glycosyltransferase After the glycosyltransferase is identified, it is contacted with the acceptor moiety and donor moiety under conditions sufficient to effect transfer and covalently bonding of the saccharide unit to the acceptor moiety. It will be appreciated that the conditions of, for example, time, temperature, and pH appropriate and optimal for a particular saccharide unit transfer can be determined by one of skill in the art through routine experimentation. Certain co-reagents may also prove useful in effecting such transfer. For example, it is preferred that the acceptor and donor moieties be contacted with the acceptor and donor moieties.
  • glycosyltransferase in the presence of divalent cations especially manganese cations such as may be provided by MnCl 2 .
  • the glycosyltransferase is immobilized by attachment to a solid support and the acceptor and donor moieties to be contacted therewith are added thereto. As discussed above, the
  • glycosyltransferase used in accordance with the present invention is frequently a mixture of glycosyltransferases containing at least one glycosyltransferase possessing the desired activity, but purified single
  • glycosyltransferases may also be used in accordance with the present invention.
  • purified single glycosyltransferase may be immobilized.
  • acceptor are each provided in solution and contacted as solutes.
  • glycosyltransferases -- and of acceptor moieties, where necessary -- is based on the copolymerization in a neutral buffer of a water soluble prepolymer such as poly(aerylamide-co-N-acryloxysuccinimide (PAN), a
  • cross-linking diamine such as triethylenetetramine
  • glycosyltransferase as disclosed by Pollack et al., J. Am. Chem. Soc. (1980) 102:6324-36.
  • the immobilization of the enzymes on PAN is useful because small amounts of enzyme can be used, high yields of enzyme activity are obtained, and the bond between enzyme and polymer is stable.
  • More preferred methods of immobilization include immobilization of the glycosyltransferase amino groups onto solid support oxirane groups (see, e.g., Chan et al, Enzvme En ⁇ . (1980) 5: 457-460) or onto cyanogen bromide activated "SEPHADEX” or “SEPHAROSE” (Axen et al, Nature (1967) 214:1302-1304).
  • the glycosyltransferase is immobilized from a moderately purified composition containing the glycosyltransferase.
  • Extremely pure enzyme preparations ie, with specific activities in the range of 1 nMole transferred par ⁇ g protein per minute of incubation) are less efficiently immobilized covalently to solid supports, in that the percent derivatization is lower, compared to 10 or 100 times less pure
  • glycosyltransferase is specifically protected during the immobilization process.
  • the glycosyltransferase may be protected by the cation required by the enzyme, the nucleotide recognized by the enzyme, and the acceptor recognized by the enzyme.
  • a galactosyl transferase may be protected with Mn 2+ , N-acetylglucosamine and UDP during the
  • a saccharide composition prepared by contacting an acceptor moiety with a donor moiety and a glycosyltransferase can, in turn, serve as an acceptor moiety for isolating further enzymes and as an acceptor moiety to which
  • saccharide units may be transferred.
  • the addition of saccharide units to saccharide compositions prepared by such contact is preferred for the synthesis of carbohydrates and saccharide chains having greater than about three saccharide units.
  • N-acetylglucosamine the disaccharide galactosyl ⁇ 1-4 N-acetylglucosamine is prepared according to this
  • saccharide units attached to the saccharide compositions of this invention can be the same or different.
  • saccharide compositions of this invention find use in an exceedingly wide variety of applications and may be used in the same manner as saccharide compositions available from known sources. It is preferred that the saccharide compositions be employed in therapeutic and preventative treatments for mammals, such as disclosed in U.S. serial Number 07/241,012.
  • saccharide compositions of this invention are expected to find use as blocking agents for cell surface receptors in the treatment of numerous diseases of viral, bacterial, or fungal origins, such as pneumonia,
  • oligosaccharides prepared according to this invention may inhibit the attachment of pathogens such as pneumonia-causing
  • compositions should inhibit attachment.
  • saccharide compositions which can be prepared in accordance with the invention can be used in the following
  • Nutritional supplements :
  • - oral and vaginal candidiasis e.g., glucomannan complex, ⁇ -D-MAN(1-6) n branched ⁇ -(1-2) with L-RHAM, D- Gal, D-Glc, ⁇ -O-sugar
  • compositions such as foodstuff compositions, containing saccharide compositions prepared in accordance with the present invention.
  • foodstuff compositions containing saccharide compositions prepared in accordance with the present invention.
  • the saccharide composition of the invention may be present in an amount of from 10 -3 ⁇ g ml -1 to 100 mg ml -1 .
  • composition or foodstuff composition will vary in terms of the activity of the saccharide being used.
  • concentration of saccharide present in the composition will depend on the in vitro activity measured for any given compound.
  • concentration of the saccharide composition of the present invention may be determined in accordance with the known activity of the compound being added.
  • mothers milk contain the saccharide composition set forth above where it is indicated as being useful both in infant formula and as an
  • the present invention provides an improvement in commercial infant formulas by permitting the addition to these commercial infant formulas the saccharide
  • the particular saccharide composition illustrated above may be present in the commercial infant formula in an amount of 0.1 ⁇ g per ml to 1000 ⁇ g per ml. It is present in mother's milk at ca. 10 ⁇ g per ml.
  • compositions should be pyrogen free.
  • Pharmaceutical compositions in accordance to the present invention may be prepared as is known in the art so as to be suitable for oral, intravenous,
  • intramuscular, rectal, transdermal or nasal (e.g., nasal spray) administration may also be prepared for topical administration in the form of creams, ointments, suspensions, etc.
  • saccharides have been noted as being important both as commodity chemicalsin the food, textile, and petroleum industries, and as specialty chemicals, primarily in the medical field, to date, the absence of an efficient process for preparing saccharide
  • compositions has made it impossible to obtain commercial compositions containing, as an active ingredient, a saccharide composition.
  • the present invention makes such saccharide
  • compositions readily available in large quantity for the first time.
  • saccharide compositions heretofore available only in miniscule quantities, and saccharide compositions
  • the method of the present invention can be used to obtain saccharide compositions containing purity levels approaching 98 wt.% to
  • compositions containing saccharide compositions present invention present in an effective amount.
  • the present invention provides compositions containing the saccharide compositions obtained in accordance with the present invention present in the amount of at least 100 mg, preferably at least 500 mg, and up to 95 wt.% of the composition.
  • the apparatus of the present invention contains one reaction chamber in which all of the glycosyltransferases, all the preselected saccharide units and the initial acceptor moiety are combined. Due to the specificity of the
  • glycosyltransferases this mixture, given sufficient time, will produce the saccharide composition of the present invention.
  • FIGS 1, 2 and 3 illustrate more efficiently designed apparatuses which may be used in accordance with the present invention.
  • the apparatus illustrated in the figures comprise, as its basic elements, a reactor equipped with an inlet and an outlet.
  • the reactor is suitable for carrying out the sequential covalent bonding of a plurality of preselected saccharide units onto an acceptor moiety, catalyzed by a plurality of
  • glycosyltransferases specific to each covalent bonding contains at least three, preferably four, and even more preferably a number greater than four, such as five, six, seven, or more, different, glycoltransferases which are preferably immobilized.
  • the inlet means is suitable for introducing the acceptor moiety and the plurality of preselected
  • the inlet means is suitable for also introducing into the reactor the glycosyltransferases which are themselves preferably immobilized.
  • the outlet means permits discharging the saccharide composition from the reactor.
  • Figure 1 illustrates a column-type reactor charged with a solid support matrix.
  • glycosyltransferases used in the process may be either randomly distributed throughout the solid support matrix or they may be arranged in zones as illustrated in Figure 1.
  • the initial acceptor moiety shown as A in the figures
  • the preselected enzyme shown as A in the figures
  • saccharide units (shown as B, C and D in the figures) are charged into the reactor via the inlet means and passed through the solid support matrix whereupon the saccharide composition is produced due to the action of the specific glycosyltransferases and recovered via the outlet means as molecule A-B-C-D.
  • the initial acceptor moiety and the preselected saccharide unit to be attached to the initial acceptor moiety are charged at the top of the solid support matrix, with the glycosyltransferases specific to the addition of each preselected saccharide units being arranged in
  • the reactor comprises a plurality of (n) reaction zones serially connected so as to be in
  • Each reaction zone contains at least one glycosyltransferase specific to catalyze the bonding of a particular preselected
  • the initial acceptor moiety (A) and the first preselected saccharide unit (B) to be attached to the acceptor moiety are passed through the first reaction zone which comprises a
  • This first intermediate product is then
  • means for purifying 4 each intermediate product formed from the reaction mixture emanating from any given reaction zone is situated in fluid communication and between each of the reaction zones.
  • the means for purifying removes contaminants in the reaction mixtures which inhibit the efficiency of the bonding of the next preselected saccharide unit onto the intermediate product formed.
  • glycosyltransferases were purified from bovine colostrum by Sephadex G-100 gel chromatography.
  • test tube l. was also added 10 ⁇ l of 40 mm uridine diphosphate galactose and 10 ⁇ l of 40 mM
  • Test tube 1 was incubated in ice for one hour.
  • To test tube 2 was also added 10 ⁇ l of 40 mM uridine diphosphate galactose. Test tube 2 was incubated at 37°C for one hour.
  • Test tube 3 was incubated at 37°C for one hour.
  • test tubes 4 and 5 were also added 10 ⁇ l of 40 mM uridine diphosphate galactose and 10 ⁇ l of 40 mM N-- acetylglucosamine.
  • Test tubes 4 and 5 were incubated at 37°C for one hour. After incubation, the contents of the test tubes were each subjected to high voltage electrophoresis on paper saturated with sodium tetraborate. Isotopically labeled trisaccharide product was identified by its mobility, as demonstrated by the product formed in test tube 3.
  • test tubes 4 and 5 yielded the expected trisaccharide product from monosaccharide starting materials.
  • the sialic acid N-acetylneuraminate presents special problems for synthetic organic chemists seeking to incorporate it into saccharide compositions, due to the acid lability of its glycosidic bond. Synthesizing a trisaccharide from cytidine monophosphate N- acetylineuraminic acid enzymatically eliminates the synthetic problems associated with removing protecting groups under strong acidic condition.
  • an acceptor moiety N- acetylglucosamine
  • a donor moiety uridine diphosphate galactose
  • a glycosyltransferase galactosyltransferase
  • composition galactosyl ⁇ 1-4 N-acetylglucosamine
  • a second donor moiety cytidine monophosphate
  • N-acetylneuraminic acid N-acetylneuraminic acid
  • N-acetylneuraminyltransferase N-acetylneuraminyltransferase
  • test tubes 4 and 5 The synthesis of the trisaccharide product in test tubes 4 and 5 from monosaccharide starting materials is confirmed by comparison with the product of test tube 3, in which the trisaccharide is formed by contacting a disaccharide acceptor moiety (N-acetyllactosamine) with cytidine monophosphate Nacetylneuraminic acid and
  • test tube 1 illustrates that a suitable acceptor moiety is necessary for trisaccharide formation.
  • the absence of trisaccharide in test tube 1 indicates that the synthesis of the trisaccharide is, indeed, dependent upon the action of any enzyme (the glycosyltransferase) that is inactive at low temperatures.
  • pneumonia-causing bacteria can likewise be prepared by the processes of the present invention.
  • a 25% saturated ammonium sulfate cut yields a supernatant that is dialyzed to remove the ammonium sulfate.
  • the retentate is applied to a Sephadex G-200 column (2.5 x 83 cm).
  • the protein profile is determined spectrophotometrically at 280 nm, and a radioactive assay is performed to locate the fractions with transferase activity.
  • the fractions containing the single enzyme peak are pooled and concentrated 10-fold by Amicon filtration.
  • the pooled enzyme preparation is againassayed, and the protein concentrtion is determined using a BioRad assay.
  • the specific activity of the preparation is 5.3 pMoles per ⁇ g protein-min.
  • Human colostrum is centrifuged at 8700 x G for 15 minutes. The supernatant is poured through cheesecloth and 10 ml is applied to a Sephadex G-100 column (2.5 x 90 cm). The protein profile is determined
  • the fractions with the highest activity are pooled and concentrated 10-fold by Amicon filtration.
  • the pooled enzyme preparation is again assayed, and the protein concentration is determined as above.
  • the specific activity of the preparation is 15.4 pMoles per ⁇ g protein-min.
  • galactosyltransferase in place of lactose, which is the acceptor for the N-acetylglucosaminyltransferase.
  • Derivatized N-acetylglucosaminyltransferase (0.5 ml beads) is incubated under constant stirring with lactose (25 mM), UDPGlcNAc (80 ⁇ M), and MnCl 2 (10 mM) for 21 hours. This incubation is carried out in duplicate-the supernatant of one incubation is used to measure the amount of trisaccharide produced (14 ⁇ g), and the
  • the galactosyltransferase incubation contains, therefore, 14 ⁇ g of trisaccharide, 25 ⁇ M UDPgal, and 10 mM MnCl 2 . After 24 hours at room temperature, the second enzyme
  • tragacanth (III), a plant oligosaccharide used by the ton as a food additive.
  • II galNAC ⁇ 1, ⁇ (fuc ⁇ 1,2 ⁇ )gal ⁇ 1,3 ⁇ (fuc ⁇ 1,4 ⁇ ) GlcNAc ⁇ 1,3 ⁇ gal ⁇ 1,4 ⁇ glc
  • lactose which is an inexpensive and readily available disaccharid, will be synthesizede.
  • the lactose so produced will be attached to Sepharose and used as an affinity ligand will then be used to purify in part the N-acetylglucosaminyltransferase from human colostrum, or from human plasma.
  • this second transferase will be used to add N- acetylglucosamine to lactose, making the trisaccharide, which will again be attached to Sepharose. This bound trisaccharide will be used to obtain the 01,3
  • hexanolamine linker This alternative method would require that hexanolamine linkers be attached to six compounds, and that derivitizations be accomplished with six hexanolamine-containing glycosides.
  • the method requires only a single hexanolamine step, and a single derivitization of glucose-hexanolamine to Sepharose, which is a relatively uncomplicated process.
  • the order of attachment of the sugars is critical.
  • the proximal fucose that attached ⁇ 1,4 to glcNAc
  • the second fucose that attached ⁇ 1,2 to the galactose.
  • the terminal galNAc ⁇ l13 is added to complete the seven-sugar oligosaccharide. This order is required by the specificities of the
  • hexasaccharide will be used, first, to purify an ⁇ l,3 galactosyltransferase that will be derivitized with protective groups for a galactosyl-, and not an N- acetylgalactosyltransferase. This enzyme will then be used to synthesize the B-type oligosaccharide.
  • hexagalacturonans will be prepared from pectin, a common constituent of citrus rinds, and used as an affinity ligand.
  • the same affinity ligand can be used, next to isolate, from tree tissues, the xylosyltransferase that synthesizes the proximal 01,3 xylosides.
  • the xylosylated galacturonans once derivatized, will be used to isolate both the fucosyl- and galactosyltransferases that, respectively, fucosylate and galactosylate the
  • fucosylation, and galactosylation will be controlled empirically by the number of passes of the compounds through the appropriate enzyme-containing columns.
  • the number of repeat units produced will depend on the number of galacturonic acid residues used initially; this number will vary in length from four to twenty monosaccharide units.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

Procédé de préparation de compositions saccharidiques. Le procédé est réitératif et comprend les trois étapes suivantes: (i) isoler une glycosyltransférase apte à transférer à une moitié acceptrice une unité saccharide présélectionnée par la mise en contact de ladite moitié et d'un mélange soupçonné de contenir la glycosyltransférase sous des conditions aptes à lier ladite moitié et ladite glycosyltransférase et donc à isoler cette dernière, la moitié acceptrice étant une protéine, une glycoprotéine, un lipide, un glycolipide ou un glucide; (ii) utiliser la glycosyltransférase isolée pour catalyser la liaison entre la moitié acceptrice et l'unité saccharidique présélectionnée; et (iii) répéter (i) et (ii) une pluralité de fois, le produit intermédiaire obtenu lors de la première itération du procédé servant de moitié acceptrice lors de la deuxième itération.
PCT/US1991/002430 1990-04-16 1991-04-11 Compositions saccharides et procedes et appareil servant a les synthetiser WO1991016449A1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
AT91907908T ATE225402T1 (de) 1990-04-16 1991-04-11 Saccharidzusammensetzungen, verfahren und apparate zu deren synthese
EP91907908A EP0481038B1 (fr) 1990-04-16 1991-04-11 Compositions saccharides et procedes et appareil servant a les synthetiser
DE69133122T DE69133122D1 (de) 1990-04-16 1991-04-11 Saccharidzusammensetzungen, Verfahren und Apparate zu deren Synthese
BR919106345A BR9106345A (pt) 1990-04-16 1991-04-11 Composicoes de sacarideos,processos e aparelhos para sua sintese
KR1019910701867A KR920702721A (ko) 1990-04-16 1991-04-11 사카라이드 조성물, 그의 합성 방법 및 장치
NO91914766A NO914766L (no) 1990-04-16 1991-12-04 Sakkaridsammensetninger, fremgangsmaater og apparatur for fremstilling derav
FI915890A FI915890A0 (fi) 1990-04-16 1991-12-13 Sakkaridfoereningar metoder och apparat foer syntes av dem.
BG96982A BG61170B1 (bg) 1990-04-16 1992-10-15 Захариди и метод и апарат за тяхното получаване

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US50956090A 1990-04-16 1990-04-16
US509,560 1990-04-16
US07/683,810 US5180674A (en) 1990-04-16 1991-04-11 Saccharide compositions, methods and apparatus for their synthesis
USNOTFURNISHED 2006-03-02

Publications (1)

Publication Number Publication Date
WO1991016449A1 true WO1991016449A1 (fr) 1991-10-31

Family

ID=27056589

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1991/002430 WO1991016449A1 (fr) 1990-04-16 1991-04-11 Compositions saccharides et procedes et appareil servant a les synthetiser

Country Status (9)

Country Link
US (4) US5180674A (fr)
EP (1) EP0481038B1 (fr)
CN (1) CN1056530A (fr)
AR (1) AR248168A1 (fr)
IE (1) IE911263A1 (fr)
IL (1) IL97853A (fr)
NZ (1) NZ237835A (fr)
PT (1) PT97382B (fr)
WO (1) WO1991016449A1 (fr)

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993020226A1 (fr) * 1992-04-01 1993-10-14 Genzyme Limited Glycolipides, leur preparation et leur utilisation
US5278299A (en) * 1991-03-18 1994-01-11 Scripps Clinic And Research Foundation Method and composition for synthesizing sialylated glycosyl compounds
EP0619837A1 (fr) * 1991-12-20 1994-10-19 The Trustees Of The University Of Pennsylvania Procede permettant d'obtenir des glycosyltransferases
US5461143A (en) * 1991-03-18 1995-10-24 The Scripps Research Institute Oligosaccharide enzyme substrates and inhibitors: methods and compositions
WO1995033467A2 (fr) * 1994-06-06 1995-12-14 The Rockefeller University Modulateurs de l'adherence des pneumocoques aux cellules pulmonaires et vasculaires et applications diagnostiques et therapeutiques
US5646123A (en) * 1991-06-10 1997-07-08 Alberta Research Council Time dependent administration of oligosaccharide glycosides related to blood group determinants having a type I or type II core structure in reducing inflammation in a sensitized mammal arising form exposure to an antigen
US5759823A (en) * 1991-03-18 1998-06-02 Scripps Research Institute Ogligosaccharide enzyme substrates and inhibitors: methods and compostions
US5763413A (en) * 1993-03-04 1998-06-09 Mect Corporation Lewis-associated compound, process for producing the same, and anti-inflammatory
WO1998044145A1 (fr) * 1997-03-31 1998-10-08 Abbott Laboratories Technique de synthese d'oligosaccharides
WO1998043494A1 (fr) * 1997-03-31 1998-10-08 Abbott Laboratories Formulations nutritionnelles contenant des oligosaccharides
WO1998043495A1 (fr) * 1997-03-31 1998-10-08 Abbott Laboratories Formulations nutritionnelles contenant de la lacto-n-neotetraose
EP0878549A2 (fr) * 1997-04-14 1998-11-18 Chemisches Laboratorium Dr. Kurt Richter GmbH Procédé pour la fabrication enzymatique de composés fructosylés
US6319695B1 (en) 1991-10-15 2001-11-20 The Scripps Research Insitute Production of fucosylated carbohydrates by enzymatic fucosylation synthesis of sugar nucleotides; and in situ regeneration of GDP-fucose
US6368604B1 (en) 1997-09-26 2002-04-09 University Of Maryland Biotechnology Institute Non-pyrogenic derivatives of lipid A
WO2003004597A1 (fr) * 2001-07-02 2003-01-16 Hitachi, Ltd. Dispositif de synthese de chaines glucidiques
US6596477B1 (en) 1998-09-28 2003-07-22 University Of Maryland Biotechnology Institute Treatment and prevention of immunodeficiency virus infection by administration of non-pyrogenic derivatives of lipid A
EP1801118A1 (fr) * 2004-09-14 2007-06-27 Shionogi & Co., Ltd. Procédé pour la synthèse de peptides de type mucine et de glycopeptides apparentés à muc1
US7335500B2 (en) 1991-10-15 2008-02-26 The Scripps Research Institute Production of fucosylated carbohydrates by enzymatic fucosylation synthesis of sugar nucleotides; and in situ regeneration of GDP-fucose
US7700701B2 (en) 2003-05-08 2010-04-20 Toyo Boseki Kabushiki Kaisha Water-soluble polymer compound having sugar chains
US8231914B2 (en) 2003-08-26 2012-07-31 Mannatech Incorporated Antioxidant compositions and methods thereto
EP2511289A1 (fr) * 2011-04-14 2012-10-17 Universität zu Köln Procédé de glycosylation chemoenzymatique rapide de conjugués entre peptides et polymères hydrophyliques
US9968625B2 (en) 2013-02-21 2018-05-15 Jennewein Biotechnologie Gmbh Synthetic or recombinant fucosylated oligosaccarides for use in the treatment of infections
WO2022034077A1 (fr) * 2020-08-10 2022-02-17 Inbiose N.V. Production de la forme alpha-1,3 glycosylée du fuc-a1,2-gal-r

Families Citing this family (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4009630C2 (de) * 1990-03-26 1995-09-28 Reinhard Prof Dr Dr Brossmer CMP-aktivierte fluoreszierende Sialinsäuren sowie Verfahren zu ihrer Herstellung
US5583042A (en) * 1990-04-16 1996-12-10 Neose Pharmaceuticals, Inc. Apparatus for the synthesis of saccharide compositions
WO1991016449A1 (fr) 1990-04-16 1991-10-31 The Trustees Of The University Of Pennsylvania Compositions saccharides et procedes et appareil servant a les synthetiser
US6518051B1 (en) * 1991-04-11 2003-02-11 The Trustees Of The University Of Pennsylvania Saccharide compositions, methods and apparatus for their synthesis
US5667984A (en) * 1991-05-07 1997-09-16 Oxford Glycosystems Ltd. Sequencing of oligosaccharides
US5403726A (en) * 1991-07-30 1995-04-04 The Scripps Research Institute Enzymatic process for producing a galactosylβ1,3glycal disaccaride using β-galactosidase
US5438130A (en) * 1993-01-15 1995-08-01 Cambridge Neuroscience, Inc. Fucosylated guanosine disulfates as excitatory amino acid antagonists
US5409817A (en) * 1993-05-04 1995-04-25 Cytel, Inc. Use of trans-sialidase and sialyltransferase for synthesis of sialylα2→3βgalactosides
US5374541A (en) * 1993-05-04 1994-12-20 The Scripps Research Institute Combined use of β-galactosidase and sialyltransferase coupled with in situ regeneration of CMP-sialic acid for one pot synthesis of oligosaccharides
WO1995002683A1 (fr) * 1993-07-15 1995-01-26 Neose Pharmaceuticals Procede de synthese de compositions de saccharide
US5559103A (en) * 1993-07-21 1996-09-24 Cytel Corporation Bivalent sialyl X saccharides
US5472859A (en) * 1993-08-02 1995-12-05 Brown, Jr.; R. Malcolm Enzymatic method for synthesis of cellulose 1
DE4330773A1 (de) * 1993-09-10 1995-03-16 Laevosan Gmbh & Co Kg Blockierung der Anlagerung von Keimen an menschliche Zellen
US5516665A (en) * 1993-09-13 1996-05-14 The Scripps Research Institute N-acetylgalactosaminyl or N-acetylglucosaminyl transfer using N-acetylglucosaminyl-1-phosphate or N-acetylgalactosaminyl-1-phosphate as precursor and glycosyl-nucleotide regeneration
US6485930B1 (en) 1993-09-15 2002-11-26 The Scripps Research Institute Mannosyl transfer with regeneration of GDP-mannose
US5616698A (en) * 1994-01-10 1997-04-01 University Of Toronto Innovations Foundation Polymer-supported solution synthesis of oligosaccharides
US5369017A (en) * 1994-02-04 1994-11-29 The Scripps Research Institute Process for solid phase glycopeptide synthesis
MX198456B (es) * 1994-03-09 2000-09-05 Abbott Lab Animales trangenicos que producen oligosacaridos y glucoconjugados.
US6204431B1 (en) 1994-03-09 2001-03-20 Abbott Laboratories Transgenic non-human mammals expressing heterologous glycosyltransferase DNA sequences produce oligosaccharides and glycoproteins in their milk
US5750176A (en) * 1994-03-09 1998-05-12 Abbott Laboratories Transgenic non-human mammal milk comprising 2'-fucosyl-lactose
NZ279676A (en) * 1994-03-09 1998-04-27 Abbott Lab Humanized milk produced by non-human transgenic mammal transformed with a heterologous gene coding for human enzyme producing human oligosaccharides and glycoconjugates
US5545553A (en) * 1994-09-26 1996-08-13 The Rockefeller University Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them
US5834251A (en) * 1994-12-30 1998-11-10 Alko Group Ltd. Methods of modifying carbohydrate moieties
US5876980A (en) * 1995-04-11 1999-03-02 Cytel Corporation Enzymatic synthesis of oligosaccharides
US5922577A (en) * 1995-04-11 1999-07-13 Cytel Corporation Enzymatic synthesis of glycosidic linkages
US5728554A (en) * 1995-04-11 1998-03-17 Cytel Corporation Enzymatic synthesis of glycosidic linkages
US6030815A (en) * 1995-04-11 2000-02-29 Neose Technologies, Inc. Enzymatic synthesis of oligosaccharides
US6127153A (en) * 1995-06-07 2000-10-03 Neose Technologies, Inc. Method of transferring at least two saccharide units with a polyglycosyltransferase, a polyglycosyltransferase and gene encoding a polyglycosyltransferase
JP4023848B2 (ja) * 1996-03-29 2007-12-19 生化学工業株式会社 硫酸化ラクトサミンオリゴ糖の製造方法
WO1997037682A1 (fr) * 1996-04-10 1997-10-16 Cytel Corporation Acides nucleiques codant une guanosine diphospho-fucose pyrophosphorylase
US6433161B1 (en) 1997-04-29 2002-08-13 Hercules Incorporated Galactosylated hydroxyalkyl polysaccharides
ATE296315T1 (de) 1997-06-24 2005-06-15 Genentech Inc Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung
US20040191256A1 (en) * 1997-06-24 2004-09-30 Genentech, Inc. Methods and compositions for galactosylated glycoproteins
JP4003093B2 (ja) * 1997-07-29 2007-11-07 東洋紡績株式会社 糖類の製造方法
US20030166109A1 (en) * 1997-09-18 2003-09-04 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20040136986A1 (en) * 1997-10-31 2004-07-15 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
EP1028751B1 (fr) 1997-10-31 2008-12-31 Genentech, Inc. Compositions renfermant des glycoformes de glycoproteine et methodes afferentes
KR100329295B1 (ko) * 1998-01-22 2002-03-20 다니구찌 이찌로오, 기타오카 다카시 전지
US7094943B2 (en) 1998-04-27 2006-08-22 Hubert Köster Solution phase biopolymer synthesis
US6423833B1 (en) 1998-05-05 2002-07-23 Steven J. Catani Functional sugar polymers from inexpensive sugar sources and apparatus for preparing same
EP1087996B1 (fr) * 1998-06-16 2007-01-17 The Board of Regents of The University of Oklahoma Glycosulfopeptide, technique de synthese et utilisation
US7223845B2 (en) 1998-06-16 2007-05-29 The Board Of Regents Of The University Of Oklahoma Synthetic glycosulfopeptides and methods of synthesis thereof
US20030143662A1 (en) * 1998-06-16 2003-07-31 Cummings Richard D. Glycosulfopeptide inhibitors of leukocyte rolling and methods of use thereof
US7339033B2 (en) * 1998-06-26 2008-03-04 Genentech, Inc. Pro1481
ES2350063T3 (es) * 1998-12-09 2011-01-17 Phyton Holdings, Llc Método para fabricación de glicoproteínas que tienen glicosilación de tipo humano.
US20010051349A1 (en) 2000-02-17 2001-12-13 Glycominds Ltd. Combinatorial complex carbohydrate libraries and methods for the manufacture and uses thereof
US20030235884A1 (en) * 1999-06-15 2003-12-25 Cummings Richard D. Polynucleotides encoding core 1 beta3-galactosyl transferase and methods of use thereof
US6492152B1 (en) 1999-06-15 2002-12-10 The Board Of Regents Of The University Of Oklahoma Core 1 β3-galactosyl transferases and methods of use thereof
US20030059915A1 (en) * 1999-06-15 2003-03-27 Canfield William M. Core 1 beta3-galactosyl transferases and methods of use thereof
AU1431101A (en) 1999-10-04 2001-05-10 University Of Maryland Biotechnology Institute Novel adjuvant comprising a lipopolysaccharide antagonist
DK1228231T3 (da) 1999-10-26 2007-10-29 Plant Res Int Bv Mammal-type glycosylering i planter
US20020098513A1 (en) * 2000-02-17 2002-07-25 Glycominds Ltd. Combinatorial complex carbohydrate libraries and methods for the manufacture and uses thereof
US6586207B2 (en) * 2000-05-26 2003-07-01 California Institute Of Technology Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues
US20020132320A1 (en) * 2001-01-10 2002-09-19 Wang Peng George Glycoconjugate synthesis using a pathway-engineered organism
JP2005505234A (ja) * 2001-01-19 2005-02-24 ザ　ダウ　ケミカル　カンパニー 植物細胞によるヒト型糖鎖をもつ糖タンパク質の分泌生産方法
EP1367881A2 (fr) * 2001-03-06 2003-12-10 The Dow Chemical Company Cellule vegetale comportant une fonction d'addition de chaine de sucres de type animal
US6596707B2 (en) 2001-05-24 2003-07-22 Abbott Laboratories Monovalent saccharides and uses thereof
JP2005527467A (ja) 2001-08-29 2005-09-15 ネオーズ テクノロジーズ， インコーポレイテッド 新規な合成ガングリオシド誘導体およびその組成物
WO2004099231A2 (fr) 2003-04-09 2004-11-18 Neose Technologies, Inc. Methode de glycopegylation et proteines/peptides produits au moyen de ces methodes
US7214660B2 (en) * 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7897842B2 (en) 2002-03-19 2011-03-01 Plant Research International B.V. GnTIII expression in plants
AU2003219418B2 (en) 2002-03-19 2008-02-28 Stichting Dienst Landbouwkundig Onderzoek Optimizing glycan processing in plants
US20040052915A1 (en) * 2002-09-13 2004-03-18 Carlson Ting L. Use of low glycemic index sweeteners in food and beverage compositions
WO2004035605A2 (fr) 2002-10-16 2004-04-29 The Scripps Research Institute Synthese de glycoproteines
JP4006385B2 (ja) 2002-11-20 2007-11-14 株式会社日立ハイテクノロジーズ 糖鎖合成装置
AR042145A1 (es) * 2002-11-27 2005-06-08 Dow Agrociences Llc Produccion de inmunoglobulinas en plantas con una fucocilacion reducida
WO2004066808A2 (fr) * 2002-12-20 2004-08-12 Momenta Pharmaceuticals, Inc. Marqueurs de glycane utilises dans le diagnostic et la surveillance d'une maladie
JP4405736B2 (ja) 2003-01-31 2010-01-27 コニカミノルタホールディングス株式会社 データベースシステム
US7309600B2 (en) * 2003-02-12 2007-12-18 University Of Iowa Research Foundation Haemophilus influenzae sialyltransferase and methods of use thereof
MXPA05009480A (es) 2003-03-06 2006-02-22 Neose Technologies Inc Metodos y composiciones para la sintesis enzimatica de gangliosidos.
US7867541B2 (en) * 2003-04-14 2011-01-11 Mead Johnson Nutrition Company Compositions and methods of formulation for enteral formulas containing sialic acid
US7951410B2 (en) * 2003-04-14 2011-05-31 Mead Johnson Nutrition Company Enteral compositions containing caseinoglycomacropeptide having an enhanced concentration of sialic acid
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
ES2359375T3 (es) * 2003-11-04 2011-05-20 Supernus Pharmaceuticals, Inc. Formas de dosificación de dosis única diaria de trospio.
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
CA2559470A1 (fr) * 2004-03-17 2005-09-29 Cargill, Incorporated Edulcorants a faible indice glycemique et produits contenant lesdits edulcorants
JP4252922B2 (ja) * 2004-03-31 2009-04-08 株式会社日立ハイテクノロジーズ 糖鎖合成装置
US20050287639A1 (en) 2004-05-17 2005-12-29 California Institute Of Technology Methods of incorporating amino acid analogs into proteins
EP1771066A2 (fr) 2004-07-13 2007-04-11 Neose Technologies, Inc. Remodelage de peg ramifie et glycosylation de peptide-1 semblable a glucagon glp-1
JP2008516637A (ja) * 2004-10-20 2008-05-22 ザ スクリップス リサーチ インスティテュート 真正細菌へのｎ−アセチルガラクトサミンアミノ酸のインビボ部位特異的組込み
US20080176790A1 (en) 2004-10-29 2008-07-24 Defrees Shawn Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf)
US9029331B2 (en) * 2005-01-10 2015-05-12 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
CA2597886C (fr) * 2005-02-15 2016-01-26 Cargill, Incorporated Procedes de fabrication de sirops
TWI264608B (en) * 2005-04-08 2006-10-21 Delta Electronics Inc Light tunnel module
EP1871795A4 (fr) * 2005-04-08 2010-03-31 Biogenerix Ag Compositions et méthodes utilisées pour la préparation de mutants par glycosylation de l'hormone de croissance humaine résistant à la protéase
EP1937719A4 (fr) * 2005-08-19 2010-11-24 Novo Nordisk As Facteur vii et facteur viia glycopégylé
US20070105755A1 (en) * 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
WO2007056191A2 (fr) 2005-11-03 2007-05-18 Neose Technologies, Inc. Purification de sucre de nucleotide en utilisant des membranes
AU2007248680C1 (en) 2006-05-02 2014-01-23 Allozyne, Inc. Non-natural amino acid substituted polypeptides
US7605255B2 (en) 2006-06-29 2009-10-20 Alberta Research Council Inc. Non-animal based lactose
US20080242607A1 (en) * 2006-07-21 2008-10-02 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
US20100075375A1 (en) * 2006-10-03 2010-03-25 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
JP5457185B2 (ja) * 2006-10-04 2014-04-02 ノヴォ ノルディスク アー／エス グリセロール連結のｐｅｇ化された糖および糖ペプチド
DK2144923T3 (da) * 2007-04-03 2013-05-13 Biogenerix Ag Behandlingsfremgangsmåder under anvendelse af glycopegyleret g-csf
BRPI0810443A2 (pt) 2007-04-17 2016-09-27 Plant Res Int Bv glicosilação do tipo em mamífero em plantas através da expressão de glicosiltransferases de não mamíferos
WO2008154639A2 (fr) 2007-06-12 2008-12-18 Neose Technologies, Inc. Procédé amélioré pour la production de sucres de nucléotide
SG185948A1 (en) * 2007-11-08 2012-12-28 Nestec Sa Use of oligosaccharides containing n-acetyllactosamine for maturation of immune responses in neonates
EP2060257A1 (fr) * 2007-11-08 2009-05-20 Nestec S.A. Prévention et traitement d'infections secondaires à la suite d'une infection virale
JP5647899B2 (ja) * 2008-01-08 2015-01-07 ラツィオファルム ゲーエムベーハーｒａｔｉｏｐｈａｒｍ ＧｍｂＨ オリゴサッカリルトランスフェラーゼを使用するポリペプチドの複合糖質化
CA2715465C (fr) 2008-02-27 2017-03-21 Novo Nordisk A/S Molecules de facteur viii conjuguees
PT2265135T (pt) 2008-03-14 2018-02-21 Nestec Sa Mistura simbiótica
WO2010051227A1 (fr) * 2008-10-29 2010-05-06 Centocor Ortho Biotech Inc. Compositions de galactose-alpha (1-3)-galactose
WO2010111530A1 (fr) 2009-03-25 2010-09-30 Seneb Biosciences, Inc. Glycolipides en tant que traitement de maladies
JP6173911B2 (ja) 2010-09-10 2017-08-09 メディミューン リミテド 抗体誘導体
EP2465509A1 (fr) 2010-11-23 2012-06-20 Nestec S.A. Composition comprenant des oligosaccharides pour le traitement des infections des voies respiratoires aiguës
EP2465507A1 (fr) 2010-11-23 2012-06-20 Nestec S.A. Composition comportant des oligosaccharides pour le traitement des maladies de la peau
EP2454948A1 (fr) 2010-11-23 2012-05-23 Nestec S.A. Mélange oligosaccharide et produit alimentaire comportant ce mélange, spécialement une formule pour enfants
EP2465508A1 (fr) 2010-11-23 2012-06-20 Nestec S.A. Composition comportant des protéines hydrolysées et oligosaccharides pour le traitement des maladies de la peau
PL2768314T3 (pl) 2011-10-18 2016-05-31 Nestec Sa Kompozycja do zastosowania do zwiększania wrażliwości na insulinę i/lub zmniejszania oporności na insulinę
US20140271562A1 (en) 2011-10-18 2014-09-18 Nestec S.A. Composition for use in brain growth and/or cognitive and/or psychomotor development
MX354727B (es) 2011-10-18 2018-03-16 Nestec Sa Composicion para uso en la promocion de absorcion de magnesio y/o retencion de magnesio.
WO2013057062A1 (fr) 2011-10-18 2013-04-25 Nestec S.A. Composition destinée à être utilisée pour favoriser l'angiogenèse intestinale et l'absorption de substances nutritives et la tolérance à l'alimentation entérale et/ou pour la prévention et/ou le traitement d'une inflammation intestinale et/ou pour la récupération après lésion et chirurgie intestinales
BR112014009097A2 (pt) 2011-10-18 2017-04-18 Nestec Sa composição para uso na promoção de crescimento de osso saudável e/ou na prevenção e/ou tratamento das doenças dos ossos
SG10201702387YA (en) 2012-09-24 2017-04-27 Medimmune Ltd Cell lines
US20140115728A1 (en) 2012-10-24 2014-04-24 A. Joseph Tector Double knockout (gt/cmah-ko) pigs, organs and tissues
WO2015071401A1 (fr) 2013-11-15 2015-05-21 Nestec S.A. Compositions destinées à être utilisées pour prévenir ou traiter l'entérocolite nécrosante chez le nourrisson ou le jeune enfant né par césarienne
ES2857077T3 (es) 2013-11-15 2021-09-28 Nestle Sa Composiciones para su uso en la prevención o tratamiento de infecciones del TRS en bebés o niños jóvenes en riesgo
MX2016006221A (es) 2013-11-15 2016-08-08 Nestec Sa Composiciones para usar en la prevencion o tratamiento de la enterocolitis necrotizante en infantes y niños pequeños.
WO2016139328A1 (fr) 2015-03-05 2016-09-09 Nestec S.A. Compositions pour utilisation dans la prévention ou le traitement de l'otite ou de la bronchite chez les nouveau-nés et les jeunes enfants
EP3264923B1 (fr) 2015-03-05 2023-01-11 Société des Produits Nestlé S.A. Compositions pour utilisation dans la prévention ou le traitement d'infections gastro-intestinales chez des bébés ou des enfants en bas âge
AU2016227596B2 (en) 2015-03-05 2020-01-16 Société des Produits Nestlé S.A. Compositions for use in improving stool consistency or frequency in infants or young children
MX2018015187A (es) 2016-08-04 2019-04-24 Nestec Sa Composiciones nutricionales con 2fl y lnnt para su uso en la prevencion y/o tratamiento de la diarrea no causada por rotavirus mediante la accion en la disbiosis de la microbiota intestinal.
CN109640702A (zh) 2016-09-07 2019-04-16 雀巢产品技术援助有限公司 用于婴儿和/或幼儿的包含低聚糖的营养组合物
US11253530B2 (en) 2017-05-09 2022-02-22 Societe Des Produits Nestle S.A. Synergistic production of butyrate associated with the complexity of HMOS blend for use in infants or young children for health purposes
US11026444B2 (en) 2017-05-24 2021-06-08 Societe Des Produits Nestle S.A. Composition comprising human milk oligosaccharides (HMO) for use in the improvement of short term memory and other cognitive benefits
MX2019011334A (es) 2017-05-24 2019-10-30 Nestle Sa Composicion que comprende oligofructosa (of) para usar en la mejora de la memoria a corto plazo y otros beneficios congnitivos.
US11260067B2 (en) 2017-05-24 2022-03-01 Societe Des Produits Nestle S.A. Methods and compositions for decreasing concentrations of detrimental proteolytic metabolites, treating health disorders, and/or promoting health benefits in infants or young children
EP3727399A1 (fr) 2017-12-21 2020-10-28 Société des Produits Nestlé S.A. Compositions destinées à être utilisées pour favoriser la croissance et le développement des muscles intestinaux et la motilité intestinale associée
WO2019122178A1 (fr) 2017-12-21 2019-06-27 Societe Des Produits Nestle S.A. Compositions comprenant au moins un oligosaccharide n-acétylé et au moins un oligosaccharide fucosylé destinées à être utilisées dans la promotion de la capacité digestive chez les nourrissons et les jeunes enfants
EP3727038A1 (fr) 2017-12-22 2020-10-28 Société des Produits Nestlé S.A. Compositions destinées à être utilisées dans la réduction de la nociception chez des nourrissons et des enfants en bas âge
MX2020012348A (es) 2018-06-25 2021-01-20 Nestle Sa Composicion que comprende oligosacaridos de la leche humana para uso en la mejora, refuerzo, promocion o modulacion de una funcion gabaergica en el sistema nervioso central.
AU2019296552B2 (en) 2018-06-25 2024-10-10 Societe Des Produits Nestle S.A. Composition comprising human milk oligosaccharides for use in improving, enhancing, promoting or modulating a serotonergic function in the central nervous system
WO2020108915A1 (fr) 2018-11-30 2020-06-04 Societe Des Produits Nestle S.A. Composition nutritionnelle pour nourrisson destinée à être utilisée dans l'amélioration de la maturation pancréatique et de la biosynthèse de l'insuline
EP3897205A1 (fr) 2018-12-21 2021-10-27 Société des Produits Nestlé S.A. Composition nutritionnelle comprenant du 6'sl et du lnt en combinaison permettant d'améliorer la fonction de barrière gastro-intestinale
DE202019005475U1 (de) 2018-12-21 2020-09-23 Société des Produits Nestlé S.A. Eine Nahrungsmittelzusammensetzung umfassend 2'-Fucosyllactose zur Verbesserung der gastrointestinalen Barriere
AU2019407214A1 (en) 2018-12-21 2021-06-10 Societe Des Produits Nestle S.A. A nutritional composition comprising metabolites of HMOs to improve the gastrointestinal barrier
AU2020230410A1 (en) 2019-03-05 2021-09-02 Société des Produits Nestlé S.A. A nutritional composition for use to enhance executive function
JP2022551829A (ja) 2019-10-17 2022-12-14 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 高度加水分解された乳児用フォーミュラ
WO2021074375A1 (fr) 2019-10-17 2021-04-22 Société des Produits Nestlé S.A. Préparation pour nourrissons
US20230000126A1 (en) 2019-12-11 2023-01-05 Societe Des Produits Nestle S.A. Compositions for use in the reduction of nociception and other health benefits in infants and young children
CN114760861A (zh) 2019-12-30 2022-07-15 雀巢产品有限公司 婴儿配方食品
AU2021359711A1 (en) 2020-10-16 2023-03-23 Société des Produits Nestlé S. A. Nutritional composition comprising human milk oligosaccharides
BR112023005888A2 (pt) 2020-10-16 2023-05-02 Nestle Sa Fórmula para bebês ou crianças pequenas
CA3192767A1 (fr) 2020-11-10 2022-05-19 Societe Des Produits Nestle S.A. Composition nutritionnelle
CN116583187A (zh) 2020-12-18 2023-08-11 雀巢产品有限公司 用于促进幼儿中加速的丁酸盐生产的组合物
WO2023278441A1 (fr) 2021-06-29 2023-01-05 The Broad Institute, Inc. Micro-organismes transitoires de bifidobacterium longum, compositions et utilisations de ceux-ci
WO2023237305A1 (fr) 2022-06-09 2023-12-14 Société des Produits Nestlé S.A. Composition nutritionnelle avec gos et hmos
WO2024165630A1 (fr) 2023-02-07 2024-08-15 N.V. Nutricia Composition nutritionnelle à résistance à la séparation améliorée

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261976A (en) * 1978-10-03 1981-04-14 The Massachusetts General Hospital Method and glycoprotein composition for inhibition of growth of transformed cells and tumors
US4563445A (en) * 1981-07-08 1986-01-07 Choay S.A. 3-Fucosyl-N-acetyl lactosamine derivatives, and their biological applications
US4770994A (en) * 1982-07-30 1988-09-13 Abbott Laboratories Determination of carbohydrate acceptors
WO1989009275A1 (fr) * 1988-03-24 1989-10-05 Nilsson Kurt G I Procede de synthese d'oligosaccharides
US4925796A (en) * 1986-03-07 1990-05-15 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3338792A (en) 1963-07-30 1967-08-29 Exxon Production Research Co Fermentation process utilizing pathogenic organisms
US3666627A (en) * 1968-10-14 1972-05-30 Corning Glass Works Method of stabilizing enzymes
BE759062A (fr) 1969-11-17 1971-05-17 Hayashibara Ken Production d'aliments et de boissons edulcorees
US4184917A (en) * 1974-04-01 1980-01-22 Sandoz Ltd. Process for producing a structurally modified interferon
US3930950A (en) * 1974-04-09 1976-01-06 The Ohio State University Research Foundation Method of immobilizing an enzyme
US4150116A (en) 1978-02-21 1979-04-17 Forsyth Dental Infirmary For Children Immunization against dental caries with glucosyltransferase antigens
JPS54144222A (en) 1978-04-28 1979-11-10 Iwasaki Kosei Pusheddout writing implement
US4219571A (en) * 1978-06-15 1980-08-26 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Process for producing a sweetener
ATE6163T1 (de) 1979-11-07 1984-02-15 Tate & Lyle Public Limited Company Herstellung von isomaltulose.
US4250262A (en) * 1979-12-14 1981-02-10 Forsyth Dental Infirmary For Children Method of preparing a purified glucosyltransferase
JPS5836959B2 (ja) * 1980-08-21 1983-08-12 三井製糖株式会社 固定化α−グルコシルトランスフエラ−ゼによるパラチノ−スの製造法
FR2535324A1 (fr) 1982-10-27 1984-05-04 Choay Sa Station perfectionnee pour l'epuration d'eaux usees
US4818816A (en) 1981-04-28 1989-04-04 Choay, S.A. Process for the organic synthesis of oligosaccharides and derivatives thereof
JPS58870A (ja) * 1981-06-20 1983-01-06 Hayashibara Biochem Lab Inc 飲食物及びその製造方法
JPS5872598A (ja) 1981-10-26 1983-04-30 Hayashibara Biochem Lab Inc 高純度イソマルト−スの製造方法
US4451566A (en) * 1981-12-04 1984-05-29 Spencer Donald B Methods and apparatus for enzymatically producing ethanol
JPS58149697A (ja) * 1982-02-27 1983-09-06 Dainippon Ink & Chem Inc β−１，３グリコシルステビオシドの製造方法
JPS58170493A (ja) 1982-04-01 1983-10-07 Yamasa Shoyu Co Ltd ３′−デオキシグアノシンの製造法
US4569909A (en) * 1982-06-03 1986-02-11 Seitetsu Kagaku Co., Ltd. Process for preparing uridine diphosphate-N-acetylgalactosamine
JPS59118053A (ja) * 1982-12-24 1984-07-07 Hayashibara Biochem Lab Inc 飲食物とその製造方法
US4678747A (en) 1983-02-18 1987-07-07 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies for detection of an H (O) blood group antigen
US4557927A (en) * 1983-03-10 1985-12-10 Kabushiki Kaisha Hoyashibara Food products and process for producing same
JPS59187792A (ja) 1983-04-11 1984-10-24 Meito Sangyo Kk 酵素法リン脂質糖類誘導体の製法
JPS59187787A (ja) 1983-04-11 1984-10-24 Meito Sangyo Kk 酵素法スフインゴリン脂質誘導体の製法
US4683297A (en) 1983-06-07 1987-07-28 Daicel Chemical Industries Ltd. Process for the preparation of glycosides
GB8316790D0 (en) * 1983-06-21 1983-07-27 Tate & Lyle Plc Chemical process
US4757012A (en) 1983-06-28 1988-07-12 Genentech, Inc. Ascorbic acid intermediates and process enzymes
SE8304006D0 (sv) * 1983-07-15 1983-07-15 Karlsson Karl Anders Forening och komposition for terapeutisk eller diagnostisk anvendning samt forfarande for terapeutisk behandling
JPS60114193A (ja) 1983-11-22 1985-06-20 Toyo Jozo Co Ltd 新規なマルトースデヒドロゲナーゼおよびその製法それを用いる分析法
HU194939B (en) 1983-12-22 1988-03-28 Chinoin Gyogyszer Es Vegyeszet Process for producing alpha- beta- and gamma cyclodextrine of high yield capacity
US4863445A (en) * 1984-07-30 1989-09-05 Baxter Travenol Laboratories, Inc. Assembly for inhibiting microbial growth in collected fluid
DE3446380C1 (de) * 1984-12-19 1986-05-22 Pfeifer & Langen, 5000 Köln Suessungsmittel,Verfahren zur Herstellung und Verwendung desselben
US4868104A (en) 1985-09-06 1989-09-19 Syntex (U.S.A.) Inc. Homogeneous assay for specific polynucleotides
SE451849B (sv) * 1985-12-11 1987-11-02 Svenska Sockerfabriks Ab Sett att syntetisera glykosidiska bindningar samt anvendning av pa detta sett erhallna produkter
US4912093A (en) 1986-10-01 1990-03-27 Marion Laboratories, Inc. Use of synthetic sulfated saccharides to enhance wound healing
DK617386A (da) 1985-12-26 1987-06-27 Takeda Chemical Industries Ltd Fremgangsmaade til fremstilling af 2-keto-d-glucarsyre
US4851517A (en) 1986-02-26 1989-07-25 Monsanto Company Tissue plasminogen activator oligosaccharide from normal human colon cells
US5272066A (en) 1986-03-07 1993-12-21 Massachusetts Institute Of Technology Synthetic method for enhancing glycoprotein stability
US4738414A (en) * 1986-03-10 1988-04-19 Controlled Parasailing Corporation Of America Parasailing assembly and system and launching the same
DE3626213A1 (de) 1986-08-02 1988-02-04 Hoechst Ag Enzymatische synthese von cyclodextrinen mit (alpha)-glucosylfluorid als substrat fuer cyclodextrin-(alpha)(1->4)glucosyltransferase
US4865976A (en) 1986-09-10 1989-09-12 Uop Method of cyclodextrin manufacture using an immobilized cyclodextrin glycosyltransferase
JPS63185352A (ja) 1986-09-30 1988-07-30 Taiho Akira 腫瘍の予防効果を有する食品
JPS63109789A (ja) * 1986-10-27 1988-05-14 Yakult Honsha Co Ltd オリゴ糖の製造法
US4835264A (en) 1986-12-12 1989-05-30 National Jewish Center Synthesis of 3,6-Di-O-methyl-D-glucose and compounds formed thereby
DE3644401A1 (de) 1986-12-24 1988-07-07 Boehringer Mannheim Gmbh Neue hydrolase-substrate
NL8701616A (nl) * 1987-07-09 1989-02-01 Stamicarbon Fructosyltransferase en bereiding van fructose-oligomeren daarmee.
JP2605295B2 (ja) * 1987-08-18 1997-04-30 スズキ株式会社 自動車の車種判別方法
US4855128A (en) 1988-01-14 1989-08-08 Warner-Lambert Company Saccharide inhibition of dental plaque
JPH0698012B2 (ja) 1988-05-13 1994-12-07 農林水産省食品総合研究所長 複分岐グルコシルーサイクロデキストリンの製法
US5217715A (en) 1988-08-01 1993-06-08 The United States Of America As Represented By The Department Of Health And Human Services Carbohydrate receptor for bacteria and method for use thereof
US5874261A (en) 1988-09-02 1999-02-23 The Trustees Of The University Of Pennsylvania Method for the purification of glycosyltransferases
DK626488D0 (da) * 1988-11-10 1988-11-10 Torben Falck Oerntoft Fremgangsmaade til udtagning af en sekretproeve via en legemsaabning og til praeparation af proeven med henblik paa kvantitativ bestemmelse af molekylaere strukturer og enzymaktivitet i proeven samt proeveudtagningsindretning til brug derved
US5047335A (en) * 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5002759A (en) 1989-07-25 1991-03-26 Colgate-Palmolive Company Oligosaccharide inhibition of Streptococcus pyogenes adhesion
ATE188999T1 (de) * 1990-02-14 2000-02-15 Univ Michigan Verfahren und produkte für die synthese von oligosaccharidstrukturen auf glykoproteinen, glykolipiden oder als freie moleküle
WO1991016449A1 (fr) * 1990-04-16 1991-10-31 The Trustees Of The University Of Pennsylvania Compositions saccharides et procedes et appareil servant a les synthetiser
US5583042A (en) 1990-04-16 1996-12-10 Neose Pharmaceuticals, Inc. Apparatus for the synthesis of saccharide compositions
DE69233654D1 (de) 1991-04-19 2006-10-19 Univ Leland Stanford Junior Zusammensetzungen und methoden für die verknüpfung von endothelzellen
US5308460A (en) * 1992-10-30 1994-05-03 Glyko, Incorporated Rapid synthesis and analysis of carbohydrates
JP2001124572A (ja) 1999-10-29 2001-05-11 Nippon Seiki Co Ltd 車両用ナビゲーション装置

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261976A (en) * 1978-10-03 1981-04-14 The Massachusetts General Hospital Method and glycoprotein composition for inhibition of growth of transformed cells and tumors
US4563445A (en) * 1981-07-08 1986-01-07 Choay S.A. 3-Fucosyl-N-acetyl lactosamine derivatives, and their biological applications
US4770994A (en) * 1982-07-30 1988-09-13 Abbott Laboratories Determination of carbohydrate acceptors
US4925796A (en) * 1986-03-07 1990-05-15 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
WO1989009275A1 (fr) * 1988-03-24 1989-10-05 Nilsson Kurt G I Procede de synthese d'oligosaccharides

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, Volume 109, Number 17, issued 24 October 1988, KRIVAN et al., "Many pulmonary pathogenic bacteria bind specifically to the carbohydrate sequence Ga1NAc beta1-4 Gal found in some glycolipids", see page 421, column 2, Abstract No. 146217S, & Proc. Natl. Acad. Sci. U.S.A., 85(16), pages 6157-6. *
CHEMICAL ABSTRACTS, Volume 114, Number 9, issued 04 March 1991, DE STEFANO et al., "Analysis of Pneumocystis carinii cyst wall. II. Sugar Composition", see pages 389 and 390, columns 2 and 1, Abstract No. 78313w, & J. Protozool., 37(5), 436-41. *
CHEMICAL ABSTRACTS, Volume 91, Number 13, issued 24 September 1979, CHATTERJEE et al., "Gycosyltransferase and glycosidase activities in ovarian cancer", see page 446, column 1, Abstract No. 1063004, & Cancer Res., 36(6,PT.1), 1943-51. *
CHEMICAL ABSTRACTS, Volume 94, Number 15, issued 13 April 1981, IMAM et al., "Isolation and Characterization of a major glycoprotein from milk-fat-globule membrane of human breast milk", see page 229, columns 1 and 2, Abstract No. 116282p, & Biochemistry Journal, 193(1), 47-54. *
Journal of Biochemistry, Volume 102, Number 3, issued 1987, SUGANUMA et al., "Purification and Properties of N-Acetyl-glucosaminide B1->4 Galactosyltransferase from Embryonal Carcinoma Cells", pages 665-671. *
The Journal of Biological Chemistry, Volume 247, Number 22, issued 25 November 1972, BARKER et al., "Agarose Derivatives of Uridine Diphosphate and N-Acetyl-glucosamine for the Purification of a Galactosyltransferase", pages 7135-7147, see entire document. *

Cited By (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874261A (en) * 1988-09-02 1999-02-23 The Trustees Of The University Of Pennsylvania Method for the purification of glycosyltransferases
US5278299A (en) * 1991-03-18 1994-01-11 Scripps Clinic And Research Foundation Method and composition for synthesizing sialylated glycosyl compounds
US5461143A (en) * 1991-03-18 1995-10-24 The Scripps Research Institute Oligosaccharide enzyme substrates and inhibitors: methods and compositions
US6168934B1 (en) 1991-03-18 2001-01-02 The Scripps Research Institute Oligosaccharide enzyme substrates and inhibitors: methods and compositions
US5759823A (en) * 1991-03-18 1998-06-02 Scripps Research Institute Ogligosaccharide enzyme substrates and inhibitors: methods and compostions
US5646123A (en) * 1991-06-10 1997-07-08 Alberta Research Council Time dependent administration of oligosaccharide glycosides related to blood group determinants having a type I or type II core structure in reducing inflammation in a sensitized mammal arising form exposure to an antigen
US7335500B2 (en) 1991-10-15 2008-02-26 The Scripps Research Institute Production of fucosylated carbohydrates by enzymatic fucosylation synthesis of sugar nucleotides; and in situ regeneration of GDP-fucose
US6319695B1 (en) 1991-10-15 2001-11-20 The Scripps Research Insitute Production of fucosylated carbohydrates by enzymatic fucosylation synthesis of sugar nucleotides; and in situ regeneration of GDP-fucose
EP0619837A4 (en) * 1991-12-20 1995-11-15 Univ Pennsylvania A method for obtaining glycosyltransferases.
EP0619837A1 (fr) * 1991-12-20 1994-10-19 The Trustees Of The University Of Pennsylvania Procede permettant d'obtenir des glycosyltransferases
US5627271A (en) * 1992-04-01 1997-05-06 Genzyme Limited Glycolipids, their preparation and use
WO1993020226A1 (fr) * 1992-04-01 1993-10-14 Genzyme Limited Glycolipides, leur preparation et leur utilisation
US5763413A (en) * 1993-03-04 1998-06-09 Mect Corporation Lewis-associated compound, process for producing the same, and anti-inflammatory
WO1995033467A3 (fr) * 1994-06-06 1996-01-04 Univ Rockefeller Modulateurs de l'adherence des pneumocoques aux cellules pulmonaires et vasculaires et applications diagnostiques et therapeutiques
US5665561A (en) * 1994-06-06 1997-09-09 The Rockefeller University Modulators of pneumococcal adherence to pulmonary and vascular cells and diagnostic and therapeutic applications
WO1995033467A2 (fr) * 1994-06-06 1995-12-14 The Rockefeller University Modulateurs de l'adherence des pneumocoques aux cellules pulmonaires et vasculaires et applications diagnostiques et therapeutiques
AU711947B2 (en) * 1994-06-06 1999-10-28 Rockefeller University, The Modulators of pneumococcal adherence to pulmonary and vascular cells and diagnostic and therapeutic applications
US6083934A (en) * 1997-03-31 2000-07-04 Abbott Laboratories Nutritional formulations containing lacto-N-neotetraose
WO1998044145A1 (fr) * 1997-03-31 1998-10-08 Abbott Laboratories Technique de synthese d'oligosaccharides
US5906982A (en) * 1997-03-31 1999-05-25 Abbott Laboratories Nutritional formulations containing Lacto-N-neoTetraose
US5945314A (en) * 1997-03-31 1999-08-31 Abbott Laboratories Process for synthesizing oligosaccharides
WO1998043494A1 (fr) * 1997-03-31 1998-10-08 Abbott Laboratories Formulations nutritionnelles contenant des oligosaccharides
US6146670A (en) * 1997-03-31 2000-11-14 Abbott Laboratories Nutritional formulations containing oligosaccharides
WO1998043495A1 (fr) * 1997-03-31 1998-10-08 Abbott Laboratories Formulations nutritionnelles contenant de la lacto-n-neotetraose
EP0878549A3 (fr) * 1997-04-14 2000-09-27 Chemisches Laboratorium Dr. Kurt Richter GmbH Procédé pour la fabrication enzymatique de composés fructosylés
EP0878549A2 (fr) * 1997-04-14 1998-11-18 Chemisches Laboratorium Dr. Kurt Richter GmbH Procédé pour la fabrication enzymatique de composés fructosylés
US6368604B1 (en) 1997-09-26 2002-04-09 University Of Maryland Biotechnology Institute Non-pyrogenic derivatives of lipid A
US6841345B1 (en) 1997-09-26 2005-01-11 University Of Maryland Biotechnology Institute Treatment and prevention of immunodeficiency virus infection by administration of non-pyrogenic derivatives of lipid A
US6596477B1 (en) 1998-09-28 2003-07-22 University Of Maryland Biotechnology Institute Treatment and prevention of immunodeficiency virus infection by administration of non-pyrogenic derivatives of lipid A
WO2003004597A1 (fr) * 2001-07-02 2003-01-16 Hitachi, Ltd. Dispositif de synthese de chaines glucidiques
EP1405905A1 (fr) * 2001-07-02 2004-04-07 Hitachi, Ltd. Dispositif de synthese de chaines glucidiques
EP1405905A4 (fr) * 2001-07-02 2005-02-02 Hitachi Ltd Dispositif de synthese de chaines glucidiques
US6962809B1 (en) 2001-07-02 2005-11-08 Hitachi, Ltd. Sugar chain synthesizer
US7700701B2 (en) 2003-05-08 2010-04-20 Toyo Boseki Kabushiki Kaisha Water-soluble polymer compound having sugar chains
US8231914B2 (en) 2003-08-26 2012-07-31 Mannatech Incorporated Antioxidant compositions and methods thereto
EP1801118A4 (fr) * 2004-09-14 2009-09-02 Shionogi & Co Procédé pour la synthèse de peptides de type mucine et de glycopeptides apparentés à muc1
EP1801118A1 (fr) * 2004-09-14 2007-06-27 Shionogi & Co., Ltd. Procédé pour la synthèse de peptides de type mucine et de glycopeptides apparentés à muc1
EP2511289A1 (fr) * 2011-04-14 2012-10-17 Universität zu Köln Procédé de glycosylation chemoenzymatique rapide de conjugués entre peptides et polymères hydrophyliques
WO2012139777A1 (fr) * 2011-04-14 2012-10-18 Universität Zu Köln Procédé pour la glycosylation chimioenzymatique rapide de conjugués entre des peptides et des polymères hydrophiles
US9968625B2 (en) 2013-02-21 2018-05-15 Jennewein Biotechnologie Gmbh Synthetic or recombinant fucosylated oligosaccarides for use in the treatment of infections
WO2022034077A1 (fr) * 2020-08-10 2022-02-17 Inbiose N.V. Production de la forme alpha-1,3 glycosylée du fuc-a1,2-gal-r

Also Published As

Publication number Publication date
CN1056530A (zh) 1991-11-27
PT97382A (pt) 1992-01-31
IL97853A0 (en) 1992-06-21
US20020061550A1 (en) 2002-05-23
EP0481038A4 (en) 1993-03-03
EP0481038A1 (fr) 1992-04-22
EP0481038B1 (fr) 2002-10-02
IE911263A1 (en) 1991-10-23
AR248168A1 (es) 1995-06-30
PT97382B (pt) 1998-08-31
US6544778B2 (en) 2003-04-08
IL97853A (en) 1997-07-13
NZ237835A (en) 1993-02-25
US5288637A (en) 1994-02-22
US6331418B1 (en) 2001-12-18
US5180674A (en) 1993-01-19

Similar Documents

Publication Publication Date Title
EP0481038B1 (fr) Compositions saccharides et procedes et appareil servant a les synthetiser
US5874261A (en) Method for the purification of glycosyltransferases
US5583042A (en) Apparatus for the synthesis of saccharide compositions
Nilsson Enzymatic synthesis of oligosaccharides
Osborn et al. Lipopolysaccharide of the Gram-Negative Cell Wall: Biosynthesis of a complex heteropolysaccharide occurs by successive addition of specific sugar residues.
US6284493B1 (en) Method of synthesizing saccharide compositions
US5246840A (en) Method for synthesis of oligosaccharides
AU642253B2 (en) Saccharide compositions, methods and apparatus for their synthesis
US6518051B1 (en) Saccharide compositions, methods and apparatus for their synthesis
US5334514A (en) Process for the production of activated sialic acids
EP0798385A2 (fr) Procédé de préparation d'oligosaccharides sulfatées à base de lactosamine
Shailubhai et al. Purification and characterization of a lymph node sulfotransferase responsible for 6-O-sulfation of the galactose residues in 2′-fucosyllactose and other sialyl LewisX-related sugars
US5936075A (en) Amino-deoxy-disaccharides and amino-deoxy-oligosaccharides
Madiyalakan et al. Phosphorylation of the α1, 2-linked mannosylsaccharide by N-acetylglucosamine-1-phosphotransferase from fibroblasts occurs at the terminal mannose
Anderson Incorporation of monosaccharides into streptococcal cell wall polysaccharide
MADIYALAKAN et al. PHOSPHORYLATION OF THE al,% LINKED MANNOSYLSACCHARIDE BY N-ACETYLGLUCOSAMINE-l-PHOSPHOTIUNSFERASE FROM FIBROBIASTS OCCURS AT THE TERMINAL MANNOSE
JP2002306184A (ja) Ｎ−アセチルグルコサミニル転移酵素の製造方法

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BB BG BR CA FI HU JP KP KR NO RO SD SU

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE BF BJ CF CG CH CM DE DK ES FR GA GB GR IT LU ML MR NL SE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2062715

Country of ref document: CA

Ref document number: 915890

Country of ref document: FI

WWE Wipo information: entry into national phase

Ref document number: 1991907908

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1991907908

Country of ref document: EP

WR Later publication of a revised version of an international search report
WWE Wipo information: entry into national phase

Ref document number: 92-01310

Country of ref document: RO

WWG Wipo information: grant in national office

Ref document number: 1991907908

Country of ref document: EP